Nuvation Bio rises after securing Japan rights to brain cancer drug

Daiichi Sankyo

01/04/2026 13:16

** Shares of biotech firm Nuvation Bio NUVB.N rise 5% to $5.59 premarket

** Co says it has acquired exclusive Japan rights to safusidenib from Daiichi Sankyo, giving it global control of the experimental drug

** Safusidenib targets IDH1‑mutant glioma, a form of brain cancer where tumors grow from abnormal brain cells - NUVB

** Co says the deal lets it expand its late‑stage global study into Japan and own all past and future clinical data

** Earlier studies showed delayed disease progression and tumor shrinkage, co says

** Says it plans to present longer‑term data from a Japanese study at an upcoming medical meeting

** Co expects results from its main global trial of about 300 patients in 2029 - NUVB

** As of last close, stock down ~52% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))